TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34907633

Group type: EXPERIMENTAL
Intervention: Combination of standard treatment for COVID-19 and hemoperfusion (hemofilter, HA330 D Javfron) for 4 hours, in 3 consecutive days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard therapy for COVID-19
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination of standard treatment for COVID-19 and hemoperfusion
Number of subjects: 68
Study: 33232191

Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE), 24 weeks of supervised PAE, followed by self‐guided physical activity
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE) in cognitively impaired subgroup
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE) in total group and cognitively impaired subgroup
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist group, 24 weeks of habitual lifestyle, followed by supervised PAE
Number of subjects: 43
Study: 35678134

Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) with low Tacrolimus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mycophenolate sodium with regular Tacrolimus (MPS)
Number of subjects: 100
Study: 33589297

Group type: EXPERIMENTAL
Intervention: Recurrent COVID-19 patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group of 62 patients
Number of subjects: 33
Study: 33138203

Group type: EXPERIMENTAL
Intervention: Sleep health promotion program
Number of subjects: 218
Study: 34315062

Group type: EXPERIMENTAL
Intervention: Multidisciplinary teaching intervention (game-based learning combined with clinical situation-based teaching) for 12 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 98
Study: 35398532

Group type: EXPERIMENTAL
Intervention: Fidaxomicin (FDX) 200 mg twice daily for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vancomycin (VAN) 125 mg four times daily for 10 days followed by a 3-week vancomycin taper and pulse (VAN-T/P) regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard course of Vancomycin (VAN) 125 mg four times daily for 10 days
Number of subjects: 0
Study: 33963496

Group type: EXPERIMENTAL
Intervention: Gaussian models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data transformation and visual inspection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Gaussian models and randomization techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newly developed statistical methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gaussian mixed models
Number of subjects: 0
Study: 33126374

Group type: EXPERIMENTAL
Intervention: Clinical nursing pathway (CNP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CNP
Number of subjects: 80
Study: 34698869

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Education
Number of subjects: 320
Study: 32781433

Group type: EXPERIMENTAL
Intervention: Goal Setting (GS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 35260678

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 32985403

Group type: COMPARATOR
Intervention: Mandatory phone-call consult (PHONE)
Number of subjects: 791

Group type: COMPARATOR
Intervention: Audiovisual consult (VIDEO)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Control group (CONTROL)
Number of subjects: 791
Study: 35691214

Group type: EXPERIMENTAL
Intervention: Regulations applying only to unvaccinated adults (e.g., test fees, isolation pay, hospital prioritization)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regulations applying to all adults
Number of subjects: 0
Study: 33975993

Group type: EXPERIMENTAL
Intervention: Denosumab-biosimilar (60 mg subcutaneous every 6 months for 1 year)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Denosumab-reference (60 mg subcutaneous every 6 months for 1 year)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Denosumab-biosimilar
Number of subjects: 114

Group type: COMPARATOR
Intervention: Denosumab-reference
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Denosumab-biosimilar and Denosumab-reference
Number of subjects: 114
Study: 32533723

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 1 mg/kg
Number of subjects: 408

Group type: COMPARATOR
Intervention: Dexamethasone (DXM) 0.3 mg/kg
Number of subjects: 408
Study: 34167868

Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg) administered orally every week for 8 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo administered orally every week for 8 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 33482894

Group type: EXPERIMENTAL
Intervention: Oral melatonin, 3 mg/kg/day for 15 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 60
Study: 33607462

Group type: EXPERIMENTAL
Intervention: Experimental group with increased attention to threat and safety cues during extinction.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Experimental group during extinction recall.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups attending to the safety cue during extinction.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group during extinction recall.
Number of subjects: 65
Study: 32448392

Group type: EXPERIMENTAL
Intervention: 12-h nutrient interruption
Number of subjects: 70

Group type: COMPARATOR
Intervention: 12-h up-to-calculated-target feeding
Number of subjects: 70
Study: 32369655

Group type: EXPERIMENTAL
Intervention: 1% Acetyl zingerone (AZ) applied twice daily for 8 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (vehicle base cream) applied twice daily for 8 weeks
Number of subjects: 31
Study: 32466660

Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pill (CDDP)
Number of subjects: 160
Study: 35607923

Group type: EXPERIMENTAL
Intervention: Permobil Explorer Mini
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modified ride-on toy car
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Child Engagement in Daily Life
Number of subjects: 24
Study: 33992437

Group type: EXPERIMENTAL
Intervention: ROTAVAC
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: ROTAVAC 5D
Number of subjects: 450

Group type: COMPARATOR
Intervention: ROTARIX
Number of subjects: 450
Study: 32946503

Group type: EXPERIMENTAL
Intervention: epsilon-tau procedure
Number of subjects: 0
Study: 35041591

Group type: EXPERIMENTAL
Intervention: Paresthesia mapping lead
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Anatomic placement lead
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both lead placement groups
Number of subjects: 43
Study: 33721055

Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Se−)
Number of subjects: 32
Study: 32305794

Group type: EXPERIMENTAL
Intervention: LUD group (received 15-30° left uterine displacement after SAB, n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LUD group
Number of subjects: 60

Group type: COMPARATOR
Intervention: non-LUD group (no LUD after SAB, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: non-LUD group
Number of subjects: 60
Study: 35065657

Group type: EXPERIMENTAL
Intervention: Robotic-arm-assisted TKR with VerasenseTM
Number of subjects: 90

Group type: COMPARATOR
Intervention: Manual TKR (standard of care)
Number of subjects: 90
Study: 33453410

Group type: EXPERIMENTAL
Intervention: Urinary proteomics analysis in CKD patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Proteomics analysis of kidney tissue from a rat CKD model (5/6 nephrectomy)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Validation analyses for protein S and galectin-1
Number of subjects: 36
Study: 32880181

Group type: EXPERIMENTAL
Intervention: Milk, Cheese, Soy-based drink
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dairy or Cheese intake
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Soy-based drink intake
Number of subjects: 11
Study: 34752019

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (10 μg, 2 doses, administered 21 days apart)
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2268
Study: 32747975

Group type: EXPERIMENTAL
Intervention: TAS‐303 18 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 34292606

Group type: EXPERIMENTAL
Intervention: GSK3511294 (2, 10, 30, 100 or 300 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 33023764

Group type: EXPERIMENTAL
Intervention: High plasma levels of total mono‐unsaturated fatty acids (MUFAs)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High plasma levels of omega‐3 fatty acids
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High plasma levels of ruminant trans fatty acids
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High plasma levels of Arachidonic acid (omega‐6 fatty acid)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total saturated fatty acids
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total industrial trans fats
Number of subjects: 200
Study: 36910415

Group type: EXPERIMENTAL
Intervention: Mobile-based training
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 198
Study: 35980115

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 4541

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 4541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4541
Study: 34422088

Group type: EXPERIMENTAL
Intervention: Radiomics model based on automatic image segmentation of DCE-MRI
Number of subjects: 81
Study: 35460165

Group type: EXPERIMENTAL
Intervention: Single oral dose of trazpiroben 25 mg after intravenous rifampin 600 mg (treatment B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single oral dose of trazpiroben 25 mg (treatment A)
Number of subjects: 12
Study: 34587976

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32060166

Group type: EXPERIMENTAL
Intervention: BA and PST-informed rehabilitation intervention (BA/PS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Time-matched attention control condition
Number of subjects: 300
Study: 35726033

Group type: EXPERIMENTAL
Intervention: 800 IU/day of oral vitamin D3
Number of subjects: 102

Group type: COMPARATOR
Intervention: 400 IU/day of oral vitamin D3
Number of subjects: 102
Study: 33423600

Group type: EXPERIMENTAL
Intervention: 60‐min football
Number of subjects: 36

Group type: COMPARATOR
Intervention: 60‐min seated rest (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-fit participants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-fit participants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Football
Number of subjects: 36
Study: 32396412

Group type: EXPERIMENTAL
Intervention: six-CpG signature
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: prognostic nomogram incorporating six-CpG signature, TNM stage, and age
Number of subjects: 378
Study: 36399721

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 7013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7013
Study: 35590259

Group type: EXPERIMENTAL
Intervention: Assisted infant toilet training initiated at 0-2 months
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Assisted infant toilet training initiated during the first year of life
Number of subjects: 268
Study: 33302976

Group type: EXPERIMENTAL
Intervention: Nebulised surfactant (Bovactant, Alveofact®) administered at varying doses (10 vials at 0, 8, and 24 hours or 30 vials at 24 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebulised surfactant (Bovactant, Alveofact®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no placebo intervention)
Number of subjects: 20
Study: 33683076

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) and laser hair removal
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin and laser hair removal
Number of subjects: 150

Group type: COMPARATOR
Intervention: Laser hair removal alone
Number of subjects: 150
Study: 32170438

Group type: EXPERIMENTAL
Intervention: Vertebroplasty (V)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 93
Study: 33310565

Group type: EXPERIMENTAL
Intervention: Bilateral cochlear implants (CIs) on
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bilateral cochlear implants (CIs) off
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moving directional street sounds
Number of subjects: 18

Group type: COMPARATOR
Intervention: Static white noise
Number of subjects: 18
Study: 32432695

Group type: EXPERIMENTAL
Intervention: Coach-supported mobile intervention platform (IntelliCare) delivered over 8 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: Wait list control (treatment as usual for 8 weeks)
Number of subjects: 146
Study: 33297742

Group type: EXPERIMENTAL
Intervention: Ischemia for 60 seconds
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ischemia for 90 seconds
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ischemia for 30 seconds
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: hs-cTnI (Siemens)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 34
Study: 35872955

Group type: EXPERIMENTAL
Intervention: Prognostic Nutritional Index (PNI) < 49 (high-risk group)
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Prognostic Nutritional Index (PNI) ≥ 49 (low-risk group)
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards regression model analysis
Number of subjects: 2661
Study: 33074940

Group type: EXPERIMENTAL
Intervention: Lidocaine (group L)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (group M)
Number of subjects: 114

Group type: COMPARATOR
Intervention: 0.9% saline (group C)
Number of subjects: 114
Study: 32623510

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide nasal spray (BCQB) 90 μg per nostril, four times daily for 4 weeks
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide nasal spray (BCQB)
Number of subjects: 720
Study: 33359277

Group type: EXPERIMENTAL
Intervention: RAS inhibitors dispensed to patients with indication (77.0%)
Number of subjects: 28782

Group type: EXPERIMENTAL
Intervention: RAS inhibitors dispensed to patients without indication (29.7%)
Number of subjects: 28782

Group type: EXPERIMENTAL
Intervention: Overall population with RAS inhibitors
Number of subjects: 28782
Study: 33106049

Group type: EXPERIMENTAL
Intervention: OFDI-guided PCI
Number of subjects: 109

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 109
Study: 33348273

Group type: EXPERIMENTAL
Intervention: Sb‐PFOA
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Total PFOA or n‐PFOA
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Total PFOS, total PFOA, and Sb‐PFOA
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: PFOA and Sb‐PFOA
Number of subjects: 691
Study: 35525420

Group type: EXPERIMENTAL
Intervention: Chrono-nutritional and sleep hygiene intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual GDM care
Number of subjects: 103
Study: 33221631

Group type: EXPERIMENTAL
Intervention: risperidone + FO
Number of subjects: 37

Group type: COMPARATOR
Intervention: risperidone + placebo
Number of subjects: 37
Study: 32729763

Group type: EXPERIMENTAL
Intervention: Moderate exercise after α/β adrenergic blocker (labetalol, 100 mg orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moderate exercise plus placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion for 20 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study: 35680813

Group type: EXPERIMENTAL
Intervention: rhTPO 300 IU/(kg·d) combined with glucocorticoid
Number of subjects: 34

Group type: COMPARATOR
Intervention: rhTPO (15,000 IU/d) combined with glucocorticoid
Number of subjects: 34
Study: 33259643

Group type: EXPERIMENTAL
Intervention: Whey protein pre-meal (20 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water pre-meal
Number of subjects: 24
Study: 32690185

Group type: EXPERIMENTAL
Intervention: Creatine supplementation and resistance training (CR + RT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo and resistance training (PL + RT)
Number of subjects: 27
Study: 35866327

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 50
Study: 34745566

Group type: EXPERIMENTAL
Intervention: oxytocin 2.5 IU
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: carbetocin 100 microg
Number of subjects: 240
Study: 32258162

Group type: EXPERIMENTAL
Intervention: Forefoot strike pattern using minimalist shoes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Original strike pattern using minimalist shoes
Number of subjects: 30
Study: 36321243

Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted subcision combined with polycaprolactone-based dermal fillers
Number of subjects: 10
Study: 32245569

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 12.5 mg kg‐1 i.v. over 150 min
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 129
Study: 36221170

Group type: EXPERIMENTAL
Intervention: EVO strategy (focused must-have vaccination strategy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 34268883

Group type: EXPERIMENTAL
Intervention: Unattended 5-min rest preceding AOBP assessment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Partially attended resting office BP
Number of subjects: 90

Group type: COMPARATOR
Intervention: Resting office BP (attended and partially attended)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Casual office BP
Number of subjects: 90
Study: 32267479

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Age (per 10 years)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Chronic lymphocytic leukemia
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Clinically photodamaged skin
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: History of cutaneous squamous cell carcinoma
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Keratinocyte carcinoma risk model
Number of subjects: 872
Study: 35020542

Group type: EXPERIMENTAL
Intervention: TECNIS Eyhance IOL
Number of subjects: 50

Group type: COMPARATOR
Intervention: RayOne IOL
Number of subjects: 50
Study: 33300481

Group type: EXPERIMENTAL
Intervention: High-variation training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-variation training
Number of subjects: 16
Study: 33276378

Group type: EXPERIMENTAL
Intervention: Childhood polygenic risk score (PRS)
Number of subjects: 66963

Group type: EXPERIMENTAL
Intervention: Adult polygenic risk score (PRS)
Number of subjects: 66963
Study: 32005514

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 190

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 190

Group type: COMPARATOR
Intervention: Xenon vs Sevoflurane
Number of subjects: 190
Study: 35869551

Group type: EXPERIMENTAL
Intervention: Open-door policy implemented in intervention wards for 12 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control ward with facultative open doors.
Number of subjects: 0
Study: 32734356

Group type: EXPERIMENTAL
Intervention: Integrated Pulmonary Index (IPI) monitoring group (IM)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Capnography monitoring group (IM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard monitoring group (SM)
Number of subjects: 147
Study: 34741911

Group type: EXPERIMENTAL
Intervention: Ethical decision-making reasoning scheme intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard general course (Control group)
Number of subjects: 101
Study: 32469158

Group type: EXPERIMENTAL
Intervention: Short Stem (SS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional Stem (CS)
Number of subjects: 75
Study: 33657970

Group type: EXPERIMENTAL
Intervention: Neurological music therapy (2 times/week, 60 min/session for 3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (BA group)
Number of subjects: 40
Study: 33550668

Group type: COMPARATOR
Intervention: Good appetite
Number of subjects: 690
Study: 32779626

Group type: EXPERIMENTAL
Intervention: Computer-based Stress Management Training
Number of subjects: 142

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 142
Study: 35851489

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 33689732

Group type: EXPERIMENTAL
Intervention: Smartphone-based multifaceted quality improvement interventions
Number of subjects: 10006

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 10006
Study: 36259531

Group type: EXPERIMENTAL
Intervention: N95 respirator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 40

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall comparison of mask types
Number of subjects: 40
Study: 32909200

Group type: EXPERIMENTAL
Intervention: Clear colonoscopy surveillance (CCS)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Routine colonoscopy surveillance (RCS)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: First repeat examination (CCS)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Second repeat examination (CCS)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Third repeat examination (CCS)
Number of subjects: 1350
Study: 32535812

Group type: EXPERIMENTAL
Intervention: Selatinib (500 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Selatinib (tablets)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Selatinib (suspension)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lapatinib (tablets)
Number of subjects: 70